JP2013181019A - 有害金属***促進剤およびそれを用いた有害金属量評価方法 - Google Patents
有害金属***促進剤およびそれを用いた有害金属量評価方法 Download PDFInfo
- Publication number
- JP2013181019A JP2013181019A JP2012047562A JP2012047562A JP2013181019A JP 2013181019 A JP2013181019 A JP 2013181019A JP 2012047562 A JP2012047562 A JP 2012047562A JP 2012047562 A JP2012047562 A JP 2012047562A JP 2013181019 A JP2013181019 A JP 2013181019A
- Authority
- JP
- Japan
- Prior art keywords
- harmful metal
- harmful
- metal excretion
- citrulline
- lipoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 99
- 239000002184 metal Substances 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title abstract description 14
- 231100000614 poison Toxicity 0.000 title abstract 7
- 230000007096 poisonous effect Effects 0.000 title abstract 7
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 38
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 34
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 34
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 30
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 29
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960002173 citrulline Drugs 0.000 claims abstract description 29
- 235000013477 citrulline Nutrition 0.000 claims abstract description 29
- 239000002738 chelating agent Substances 0.000 claims abstract description 7
- 230000029142 excretion Effects 0.000 claims description 68
- 210000002700 urine Anatomy 0.000 claims description 56
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 34
- 229910052753 mercury Inorganic materials 0.000 claims description 32
- 229910052785 arsenic Inorganic materials 0.000 claims description 4
- 229910052793 cadmium Inorganic materials 0.000 claims description 4
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 3
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims 3
- 231100000331 toxic Toxicity 0.000 description 17
- 230000002588 toxic effect Effects 0.000 description 17
- 150000002739 metals Chemical class 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000004380 ashing Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 241000208308 Coriandrum Species 0.000 description 3
- 235000002787 Coriandrum sativum Nutrition 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 3
- 244000018436 Coriandrum sativum Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 2
- 238000009834 vaporization Methods 0.000 description 2
- 230000008016 vaporization Effects 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000001359 coriandrum sativum l. oleoresin Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000007892 occupational asthma Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Images
Abstract
【解決手段】本発明の有害金属***促進剤は、αリポ酸のみからなるキレート剤およびシトルリンを含むことを特徴とする。本発明の有害金属***促進剤は、例えば、前記αリポ酸を1〜1200mg、前記シトルリンを1〜3400mg含むことが好ましく、前記αリポ酸と前記シトルリンとの重量比が、1:0.5〜1:20であることが好ましい。
【選択図】図4
Description
本発明の有害金属***促進剤は、前述のように、αリポ酸のみからなるキレート剤およびシトルリンを含むことを特徴とする。本発明は、キレート剤としてαリポ酸のみを含み、シトルリンと共存させることが特徴であって、その他の構成は何ら制限されない。
本発明の有害金属***方法は、被験者に、前記本発明の有害金属***促進剤を投与する工程を含むことを特徴とする。本発明は、前記本発明の有害金属***促進剤を使用することが特徴であって、その他の構成は何ら制限されない。
本発明の有害金属量の評価方法は、前述のように、有害金属***促進剤が投与された被験者の***尿における有害金属量を測定する工程を含み、前記有害金属***促進剤が、前記本発明の有害金属***促進剤であることを特徴とする。本発明は、前記本発明の有害金属***促進剤を使用することが特徴であって、その他の構成は何ら制限されない。
有害金属***促進剤を投与した被験者から***尿を採取し、前記***尿中の水銀量を測定して、水銀***能の比較を行った。
健常な成人男女の被験者8名(A〜H)に、同じ朝食を摂取させ、午前9時に尿を***させた。その後、各被験者に、実施例1の有害金属***促進剤としてαリポ酸200mgおよびシトルリン800mgを同時に経口投与させた。そして、αリポ酸およびシトルリンの投与から、1時間後、2時間後、3時間後および4時間後に、各被験者の***尿を全量採取した。
前記被験者(A〜H)に対して、前記(1)の試験とは別の日に、αリポ酸およびシトルリンを投与しない以外は、前記実施例と同様の試験を行い、***尿中の総水銀量を算出した。
比較例1−1として、前記被験者(A〜H)に対して、前記(1)および(2)の試験とは別の日に、αリポ酸200mgおよびシトルリン800mgに代えて、比較例1−1の有害金属***促進剤としてαリポ酸200mgのみを経口投与させた以外は、前記実施例と同様に試験を行い、***尿中の総水銀量を算出した。
また、比較例1−2として、前記被験者(A〜H)に対して、前記(1)〜(3)の試験とは別の日に、αリポ酸200mgおよびシトルリン800mgに代えて、比較例1−2の有害金属***促進剤としてシトルリン800mgのみを経口投与させた以外は、前記実施例と同様に試験を行い、***尿中の総水銀量を算出した。
Claims (10)
- αリポ酸のみからなるキレート剤およびシトルリンを含むことを特徴とする有害金属***促進剤。
- 前記αリポ酸を1〜1200mg、前記シトルリンを1〜3400mg含む、請求項1記載の有害金属***促進剤。
- 前記αリポ酸と前記シトルリンとの重量比が、1:0.5〜1:20である、請求項1または2記載の有害金属***促進剤。
- 前記有害金属が、水銀、カドミウム、鉛および砒素からなる群から選択された少なくとも一つの金属である、請求項1から3のいずれか一項に記載の有害金属***促進剤。
- 経口投与に用いられる、請求項1から4のいずれか一項に記載の有配金属***促進剤。
- 少なくともαリポ酸を含むキレート剤およびシトルリンを含むことを特徴とする有害金属***促進剤。
- 有害金属***促進剤が投与された被験者の***尿における有害金属量を測定する工程を含み、
前記有害金属***促進剤が、請求項1から6のいずれか一項に記載の有害金属***促進剤であることを特徴とする有害金属量の評価方法。 - 請求項1から6のいずれか一項に記載の有害金属***促進剤を含むことを特徴とするサプリメント。
- 請求項1から6のいずれか一項に記載の有害金属***促進剤を含むことを特徴とする機能性食品。
- 請求項1から6のいずれか一項に記載の有害金属***促進剤を含むことを特徴とする食品添加物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012047562A JP5899008B2 (ja) | 2012-03-05 | 2012-03-05 | 有害金属***促進剤およびそれを用いた有害金属量評価方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012047562A JP5899008B2 (ja) | 2012-03-05 | 2012-03-05 | 有害金属***促進剤およびそれを用いた有害金属量評価方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013181019A true JP2013181019A (ja) | 2013-09-12 |
JP5899008B2 JP5899008B2 (ja) | 2016-04-06 |
Family
ID=49271931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012047562A Active JP5899008B2 (ja) | 2012-03-05 | 2012-03-05 | 有害金属***促進剤およびそれを用いた有害金属量評価方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5899008B2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3072508A1 (en) * | 2015-03-23 | 2016-09-28 | ARKRAY, Inc. | Method for predicting amount of analyte in urine specimen |
JP2016180752A (ja) * | 2015-03-23 | 2016-10-13 | アークレイ株式会社 | 尿検体中の分析対象物量の予測方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060083793A1 (en) * | 2004-09-29 | 2006-04-20 | Gardiner Paul T | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker |
US20060099239A1 (en) * | 2002-04-15 | 2006-05-11 | Coleman Henry D | Dietary supplement for promoting removal of heavy metals from the body |
WO2010029913A1 (ja) * | 2008-09-11 | 2010-03-18 | 株式会社林原生物化学研究所 | 気力改善剤 |
JP2010159240A (ja) * | 2009-01-09 | 2010-07-22 | Takashi Kodera | 哺乳動物のための組織・細胞障害修復能及び体内浄化能を有する組成物。 |
CN102356879A (zh) * | 2011-10-21 | 2012-02-22 | 深圳市俪斯生物科技有限公司 | 一种功能肽强化的保健食品 |
-
2012
- 2012-03-05 JP JP2012047562A patent/JP5899008B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060099239A1 (en) * | 2002-04-15 | 2006-05-11 | Coleman Henry D | Dietary supplement for promoting removal of heavy metals from the body |
US20060083793A1 (en) * | 2004-09-29 | 2006-04-20 | Gardiner Paul T | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker |
WO2010029913A1 (ja) * | 2008-09-11 | 2010-03-18 | 株式会社林原生物化学研究所 | 気力改善剤 |
JP2010159240A (ja) * | 2009-01-09 | 2010-07-22 | Takashi Kodera | 哺乳動物のための組織・細胞障害修復能及び体内浄化能を有する組成物。 |
CN102356879A (zh) * | 2011-10-21 | 2012-02-22 | 深圳市俪斯生物科技有限公司 | 一种功能肽强化的保健食品 |
Non-Patent Citations (1)
Title |
---|
JPN6015034247; シトルリンコンプレックス , 2009 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3072508A1 (en) * | 2015-03-23 | 2016-09-28 | ARKRAY, Inc. | Method for predicting amount of analyte in urine specimen |
JP2016180752A (ja) * | 2015-03-23 | 2016-10-13 | アークレイ株式会社 | 尿検体中の分析対象物量の予測方法 |
US11237153B2 (en) | 2015-03-23 | 2022-02-01 | Arkray, Inc. | Method for predicting amount of analyte in urine specimen |
Also Published As
Publication number | Publication date |
---|---|
JP5899008B2 (ja) | 2016-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boskabady et al. | The effect of environmental lead exposure on human health and the contribution of inflammatory mechanisms, a review | |
Bjørklund et al. | Toxic metal (loid)-based pollutants and their possible role in autism spectrum disorder | |
Clarkson et al. | The toxicology of mercury and its chemical compounds | |
Nations et al. | Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease | |
Leasure et al. | Low-level human equivalent gestational lead exposure produces sex-specific motor and coordination abnormalities and late-onset obesity in year-old mice | |
Kern et al. | Evidence supporting a link between dental amalgams and chronic illness, fatigue, depression, anxiety, and suicide | |
Gorini et al. | The role of heavy metal pollution in neurobehavioral disorders: a focus on autism | |
Lidsky et al. | Lead neurotoxicity in children: basic mechanisms and clinical correlates | |
Tiffany-Castiglioni et al. | Kohl and surma eye cosmetics as significant sources of lead (Pb) exposure | |
Taylor | Toxicological profile for cyanide | |
Pervaiz et al. | Freewheel training alters mouse hippocampal cytokines | |
Winiarska-Mieczan | Cumulative rate and distribution of Cd and Pb in the organs of adult male Wistar rats during oral exposure | |
Bagchi et al. | Effects of acute and chronic oval exposure of lead on blood pressure and bone mineral density in rats | |
JP5899008B2 (ja) | 有害金属***促進剤およびそれを用いた有害金属量評価方法 | |
Filip-Stachnik et al. | Acute effects of two caffeine doses on bar velocity during the bench press exercise among women habituated to caffeine: A randomized, crossover, double-blind study involving control and placebo conditions | |
Abu-Taweel et al. | Curcumin ameliorated the mercuric chloride induced depression and anxiety in female mice offspring | |
Nurov | Immunologic features of speleotherapy in patients with chronic obstructive pulmonary disease | |
Muganurmath et al. | Causality assessment of olfactory and gustatory dysfunction associated with intranasal fluticasone propionate: application of the Bradford Hill criteria | |
Bunout et al. | Lean and fat mass as determinants of muscle strength and insulin sensitivity in Chilean elderly subjects | |
Balachandran et al. | Rodent hair is a Poor biomarker for internal manganese exposure | |
JP2013181932A (ja) | ***尿における有害金属量の評価方法 | |
Molin et al. | Sequential effects of daily arsenic trioxide treatment on essential and nonessential trace elements in tissues in mice | |
Aslani et al. | Individual and combined effect of meso-2, 3-dimercaptosuccinic acid and allicin on blood and tissue lead content in mice | |
Zanager | Mercury leaching from dental amalgam fillings and its association with urinary zinc | |
Khan et al. | NEUROPROTECTIVE EFFICACY OF SWARNA BHASMA ON SLEEP DEPRIVED INDUCED COGNITIVE IMPAIRMENT IN RATS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141006 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151023 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160226 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160307 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5899008 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |